Detection of primary and metastatic lesions by [18F]fluoro-2-deoxy-D-glucose PET in a patient with thymic carcinoid.
We present a case of thymic carcinoid, in which primary and metastatic lesions of lymph nodes and bones could be detected by [(18)F]fluoro-2-deoxy-D-glucose (FDG)-PET, but not by (123)I-meta-iodobenzylguanidine ((123)I-MIBG) SPECT, or by (99m)Tc-methylene diphosphonate ((99m)Tc-MDP) bone scintigraphy. FDG-PET may be a useful tool for managing thymic carcinoids in patients with negative results on (123)I-MIBG SPECT or (99m)Tc-MDP imaging.
Fujishita
Takashi
T
The First Department of Internal Medicine, Faculty of Medicine, University of Toyama, Toyama, Japan. tmfuji@sea.plala.or.jp
Kishida
Mika
M
Taki
Hirofumi
H
Shinoda
Chie
C
Miyabayashi
Koutarou
K
Fujishita
Masayo
M
Maruyama
Muneharu
M
Mizushima
Yutaka
Y
Kobayashi
Masashi
M
D019797:3-Iodobenzylguanidine; D000368:Aged; D001859:Bone Neoplasms / Q000000981:diagnostic imaging* / Q000556:secondary; D002276:Carcinoid Tumor / Q000000981:diagnostic imaging* / Q000473:pathology / Q000628:therapy; D019788:Fluorodeoxyglucose F18; D006801:Humans; D007457:Iodine Radioisotopes; D008207:Lymphatic Metastasis; D008297:Male; D049268:Positron-Emission Tomography; D019275:Radiopharmaceuticals; D013669:Technetium Tc 99m Medronate; D013953:Thymus Neoplasms / Q000000981:diagnostic imaging* / Q000473:pathology / Q000628:therapy
D007457:Iodine Radioisotopes; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18; D019797:3-Iodobenzylguanidine; D013669:Technetium Tc 99m Medronate